Lynn E. Heasley

VA Eastern Colorado Health Care System — United States

Medicine · Health Sciences

55h-index11.1kcitations322works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(83), Fibroblast Growth Factor Research(60), Cancer Immunotherapy and Biomarkers(48), Protein Kinase Regulation and GTPase Signaling(31), PI3K/AKT/mTOR signaling in cancer(29)

Publications322 total

The polyamine inhibitor SAM486A increases the efficacy of adagrasib in non-small cell lung cancer cells harboring KRASG12C mutation
Biological Research·2026Open Access
YAP/TEAD drives treatment-induced adaptive immunosuppression in EGFR-mutant lung cancer
2026Open Access
High programmed death-ligand 1 expression is associated with a shorter progression free survival in ALK-rearranged lung cancer patients treated with first line tyrosine kinase inhibitors
SSRN Electronic Journal·2026Open Access
Orthotopically Implanted Murine Lung Adenocarcinoma Cell Lines for Preclinical Investigations
Cancers·2025· 1 citedOpen Access
Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma
2025· 1 citedOpen Access
Novel PLEC-EML4-ALK Double Fusion Underlying Crizotinib Resistance in a Metastatic Inflammatory Myofibroblastic Tumor: A Case Report
JTO Clinical and Research Reports·2025Open Access
Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma
SSRN Electronic Journal·2025Open Access
SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition
Science Advances·2024· 11 citedOpen Access
The pro-tumoral and anti-tumoral roles of EphA4 on T regulatory cells and tumor associated macrophages during HNSCC tumor progression
2024· 1 citedOpen Access
NVTG-09 TARGETING TRKB IN LUNG-TO-BRAIN METASTATIC PROGRESSION
Neuro-Oncology Advances·2024Open Access
High PD-L1 expression among patients with ALK rearranged non–small cell lung cancer and response to first line ALK tyrosine kinase inhibitors.
Journal of Clinical Oncology·2024
Abstract 2024: Deep and durable responses to ALK-targeted therapy require CD8+ T cells
Cancer Research·2024
Abstract 5867: Early activation of HGF-cMET serves as a bypass pathway to ALK and RET tyrosine kinase inhibitors in non-small cell lung cancer
Cancer Research·2024
A functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes
Biology Open·2023· 4 citedOpen Access
A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes
2023Open Access
Data from Nonamplified FGFR1 Is a Growth Driver in Malignant Pleural Mesothelioma
2023Open Access
Data Supplement from Nonamplified FGFR1 Is a Growth Driver in Malignant Pleural Mesothelioma
2023Open Access
Supplementary Figure Legends from Hypoxia Regulates Alternative Splicing of HIF and non-HIF Target Genes
2023Open Access
Supplementary Figure 7 from The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
2023Open Access
Supplemental File 2 from Hypoxia Regulates Alternative Splicing of HIF and non-HIF Target Genes
2023Open Access
page 1 of 17Next →

Frequent Co-authors

Gary L. Johnson(14), Lindsay A. Marek(9), Raphael A. Nemenoff(7), Trista K. Hinz(7), Raphael A. Nemenoff(6), Aik Choon Tan(6), Kathryn E. Ware(6), Eric T. Clambey(5), Laura Butterfield(5), Robert C. Doebele(4), David Raben(4), Paul A. Bunn(4), Sunil Gupta(4), Robert A. Winn(4), Dara L. Aisner(3), Anh T. Le(3), Wilbur A. Franklin(3), Marileila Varella‐Garcia(3), D. Ross Camidge(3), Ayman Oweida(3)